Inhibitors of diacylglycerol acyltransferase: a review of 2008 patents

Bibliography

• Bansal S, Buring JE, Rifai N, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007;298(3):309-16
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007:298(3):299-308
   PubMed Web of Science ®Google Scholar
• Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008;34(6 Pt 2):649-57
   PubMed Web of Science ®Google Scholar
• Kennedy EP. Metabolism of lipids. Annu Rev Biochem 1957;26:119-48
   PubMed Web of Science ®Google Scholar
• Kayden HJ, Senior JR, Mattson FH. The monoglyceride pathway of fat absorption in man. J Clin Invest 1967;46(11):1695-703
   PubMed Web of Science ®Google Scholar
• Yen CL, Stone SJ, Koliwad S, Thematic Review Series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 2008;49(11):2283-301
   PubMedGoogle Scholar
• Cases S, Smith SJ, Zheng Y-W, Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998;95(22):13018-23
   PubMed Web of Science ®Google Scholar
• Cases S, Stone SJ, Zhou P, Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001;276(42):38870-6
   PubMed Web of Science ®Google Scholar
• Smith SJ, Cases S, Jensen DR, Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT. Nat Genet 2000;25(1):87-90
   PubMed Web of Science ®Google Scholar
• Chen HC, Smith SJ, Ladha Z, Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 2002;109(8):1049-55
   PubMed Web of Science ®Google Scholar
• Chen HC, Rao M, Sajan MP, Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking Acyl CoA:diacylglycerol acyltransferase 1. Diabetes 2004;53(6):1445-51
   PubMed Web of Science ®Google Scholar
• Chen HC, Ladha Z, Smith SJ, Analysis of energy expenditure at different ambient temperatures in mice lacking DGAT-1. Am J Physiol Endocrinol Metab 2003;284(1):E213-8
   Web of Science ®Google Scholar
• Buhman KK, Smith SJ, Stone SJ, DGAT-1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002;277(28):25474-9
   PubMed Web of Science ®Google Scholar
• Bayer . Preparation and use of aryl alkyl acid derivatives for the treatment of obesity. US07091228; 2004
   Google Scholar
• Zhao G, Souers AJ, Voorbach M, Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 2008;51(3):380-3
   PubMed Web of Science ®Google Scholar
• Birch AM, Birtles S, Buckett LK, Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor. J Med Chem 2009;52(6):1558-68
   PubMed Web of Science ®Google Scholar
• King AJ, Segreti JA, Larson KJ, Diacylglycerol acyltransferase 1 (DGAT-1) inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. J Pharmacol Exp Ther 2009;330(2):526-31
   PubMed Web of Science ®Google Scholar
• Chen HC, Smith SJ, Tow B, Leptin modulates the effects of acyl CoA:diacylglycerol acyltransferase deficiency on murine fur and sebaceous glands. J Clin Invest 2002;109(2):175-81
   PubMed Web of Science ®Google Scholar
• Cases S, Zhou P, Shillingford JM, Development of the mammary gland requires DGAT-1 expression in stromal and epithelial tissues. Development 2004;131(13):3047-55
   PubMed Web of Science ®Google Scholar
• Chen HC, Farese RV Jr. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT-1-deficient mice. Arterioscler Thromb Vasc Biol 2005;25(3):482-6
   PubMed Web of Science ®Google Scholar
• Stone SJ, Myers HM, Watkins SM, Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 2004;279(12):11767-76
   PubMed Web of Science ®Google Scholar
• Yu XX, Liu ZX, Morino K, Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 2005;42(2):362-71
   PubMed Web of Science ®Google Scholar
• Liu Y, Millar JS, Cromley DA, Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim Biophys Acta 2008;1781(3):97-104
   PubMed Web of Science ®Google Scholar
• Choi CS, Savage DB, Kulkarni A, Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT-1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J Biol Chem 2007;282(31):22678-88
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Liu Y, McCall S, Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45(6):1366-74
   PubMed Web of Science ®Google Scholar
• Hubbard BK, Gilmore TA, Serrano-Wu MH. Antisense and small-molecule modulation of diacylglycerol acyltransferase. Expert Opin Ther Patent 2007;17:1331-9
   Web of Science ®Google Scholar
• Roche . Diacylglycerol acyltransferase inhibitors. WO2006120125; 2006
   Google Scholar
• Roche. Diacylglycerol acyltransferase inhibitors. WO2007060140; 2007
   Google Scholar
• Roche. Inhibitors of diacylglycerol acyltransferase. WO2006082010; 2006
   Google Scholar
• Roche. Diacylglycerol acyltransferase inhibitors. WO2008141976; 2008
   Google Scholar
• Takeda. Amide compounds. WO2008011130; 2008
   Google Scholar
• Takeda. Amide compounds. WO2008011131; 2008
   Google Scholar
• Astrazeneca. Oxadiazole derivatives as DGAT inhibitors. WO2006134317; 2006
   Google Scholar
• BMS. Use of thianecarboxamides as DGAT inhbitors. US20080090876; 2008
   Google Scholar
• Janssen. Piperidine/piperazine derivatives. WO2008148840; 2008
   Google Scholar
• Janssen. Piperidine/piperazine derivatives. WO2008148849; 2008
   Google Scholar
• Janssen. Piperidine/piperazine derivatives. WO2008148868; 2008
   Google Scholar
• Janssen. Piperidine/piperazine derivatives. WO2008148851; 2008
   Google Scholar
• Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US2007069112; 2007
   Google Scholar
• Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080015227; 2008
   Google Scholar
• Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080312282; 2008
   Google Scholar
• Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080182861; 2008
   Google Scholar
• Abbott. Inhibitors of diacyl O-acyltransferase type I enzyme. US20080293713; 2008
   Google Scholar
• Souers AJ, King AJ, Mittelstadt S, “DGAT-1 Inhibitors as Novel Therapeutics for Dyslipidemia” Western Regional ACS meeting, San Diego, 2008
   Google Scholar
• Souers AJ. “DGAT-1 Inhibitors as Novel Therapeutics for Dyslipidemia” 237th National ACS meeting, Salt Lake City, 2009
   Google Scholar
• Korea Research institute of bioscience and biotechnology. Composition for the prevention and treatment of metabolic disorder containing benzazole derivatives as an active ingredient. WO2008039008; 2008
   Google Scholar
• Korea Research institute of bioscience and biotechnology. Indol derivatives, the method for preparing thereof and composition for the prevention and treatment of metabolic disorder containing the same as an active ingredient. WO2008039007; 2008
   Google Scholar
• Bioactives. Prenylflavonoid formulations. WO2007016578; 2007
   Google Scholar
• Bioactives. Methods and compositions for treating dyslipidemia. WO2008095189; 2008
   Google Scholar
• ISIS. Modulation of diacylglycerol acyltransferase 2 expression. WO2004094618; 2004
   Google Scholar
• ISIS. Modulation of diacylglycerol acyltransferase 2 expression. US20050272680; 2005
   Google Scholar
• ISIS. Compositions and their uses directed to diacylglycerol acyltransferase I. WO2008019351; 2008
   Google Scholar
• Tularik and Japan Tobacco. Fused and bicyclic nitrogen-containing heterocycles. WO2004047755; 2004
   Google Scholar
• Available from: http://pharma.bayer.com/scripts/pages/en/news_room/news_room/archive/newsroom_archive26.php
   Google Scholar
• Available from: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view&newsId=20070827005440&newsLang=en
   Google Scholar
• Chia CW, Egan JM. Biology and therapeutic potential of GLP-1 in the treatment of diabetes. Drug Discov Today 2005;2(3):295-01
   Google Scholar
• Shih MYS, Kane MA, Zhou P, Retinol esterification by DGAT1 is essential for retinoid homeostasis in murine skin. J Biol Chem 2008;284(7):4292-9
   PubMed Web of Science ®Google Scholar
• Sankyo. Medicine containing urea derivative. JP2007191471; 2007
   Google Scholar
• Mucke H, Yeates C, Norman P. Patent alert. Current Opin Invest Drugs. 2006;7(9):781-88
   Google Scholar